Zydus Lifesciences has inked a Memorandum of Understanding with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India. The company and Guardant Health Inc., a leading precision oncology company, have an exclusive agreement to make the Shield MCD test available in India.
The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older and who are at typical average risk for cancer. With just a blood draw, the test screens for 10 of the most common cancers, many of which have high mortality rates in India. The test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), recognising its potential to provide more effective screening for cancers than existing options.
Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
